Mitochondrial protein synthesis

Mitochondrial protein synthesis is a cellular process by which mitochondria produce a subset of their own proteins using their unique genetic system. This involves transcription of mitochondrial DNA into mRNA within the matrix, followed by translation on specialized mitochondrial ribosomes distinct from cytoplasmic ones. The human mitochondrial genome encodes 13 essential hydrophobic proteins required for oxidative phosphorylation complexes; all other ~99% of mitochondrial proteins are encoded by nuclear DNA and imported into the organelle[1][3][7]. The process requires specific initiation, elongation, termination, and recycling factors unique to mitochondria. Proper coordination between nuclear and mitochondrial genomes is critical for cellular energy production. Defects in this pathway lead to a range of mitochondrial diseases, often affecting organs with high energy requirements such as brain, heart, and muscle. While not itself a druggable molecular target like an enzyme or receptor—and thus not considered a canonical therapeutic target—understanding its regulation is crucial for developing therapies against primary mitochondrial disorders. Some antibiotics can inadvertently inhibit this process due to similarities between bacterial and mitoribosomes. Note: "Mitochondrial protein synthesis" refers to a biological pathway/process rather than an individual molecule/receptor/protein; it should not be treated as a canonical drug target entity[1][2][3].

Other names

Mitochondrial translationmt-protein synthesisMitochondrial ribosomal protein synthesis

Drugs that affect mitochondrial protein synthesis generally act by inhibiting the mitoribosome or interfering with translation factors; however, no approved drugs specifically target this process for therapeutic benefit.